IP Library Patent Application 12140609
Patent Application
App. No. 12/140,609

PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/140,609
Abstract

The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.

Claims (31)

1 . A process for the production of a solid dosage form with at least reduced potential for abuse, said dosage form exhibiting a breaking strength of at least 500 N, said process comprising:

a) providing a formulation mixture comprising at least one active ingredient with potential for abuse (A) and at least one synthetic or natural polymer (C), wherein the at least one active ingredient with potential for abuse (A) is selected from the group consisting of oxvmorphone, hydromorphone, morphine and physiologically acceptable compounds and derivatives thereof,

b) moistening the mixture with at least a sufficient quantity of a solvent for the polymer (C) to uniformly moisten the mixture,

c) optionally dividing the mixture from step b) into sub-portions,

d) drying the sub-portion(s) from step c) or the mixture from step b) and

e) shaping the dried sub-portion or mixture from step d) to yield the dosage form.

2 . A process according to claim 1 , where the dried sub-portions in each case correspond to the mass of a unit of the dosage form.

3 . A process according to claim 1 , which further comprises dispersing the formulation mixture in a liquid dispersant in which the polymer component (C) is not soluble before addition of the solvent.

4 . A process according to claim 3 , which further comprises dividing the formulation mixture into sub-portions in each case corresponding to the mass of a unit of the dosage form either before or after the formulation mixture is dispersed.

5 . A process according to claim 3 , where the solvent and the dispersant are miscible with one another.

6 . A process according to claim 1 , which further comprises incorporating the solvent into the formulation mixture as a foam.

7 . A process according to claim 6 , which further comprises stabilizing the foam with the assistance of foam stabilizers.

8 . A process according to claim 6 , which further comprises drying the sub-portion(s) or the mixture in granular form.

9 . A process according to claim 8 , which further comprises drying the mixture in granular form, and then dividing the dried, granulated mixture into sub-portions, which in each case correspond to the mass of a unit of the dosage form, and shaping to yield the dosage form.

10 . A process according to claim 1 , which further comprises adding solvent to the formulation mixture in an amount such that a shapeable paste is obtained.

11 . A process according to claim 10 , which further comprises drying the paste and, before or after it is dried, dividing the paste into sub-portions and shaping or converting into the dosage form the dried portions, optionally after further dividing in each case into a portion corresponding to the mass of a unit of the dosage form.

12 . A process according to claim 11 , where the sub-portions have the form of strands.

13 . A process according to claim 12 , which further comprises producing the strands with the assistance of a screen or strand former.

14 . A process according to claim 12 , which further comprises singulating and shaping dried strands to yield the dosage form.

15 . A process according to claim 14 , where shaping proceeds with the assistance of a tablet press.

16 . A process according to claim 12 , which further comprises shaping dried strands with the assistance of shaping rollers or shaping belts equipped with rollers to yield the dosage form.

17 . A process according to claim 11 , which further comprises converting the paste into a planar structure, from which the dosage form is stamped.

18 . A process according to claim 10 , where the process is performed with the assistance of an extruder.

19 . A process according to claim 1 , which further comprises adding a quantity of solvent sufficient to dissolve at least the polymer component (C) to the formulation mixture.

20 . A process according to claim 19 , which further comprises converting the solution into a planar structure.

21 . A process according to claim 20 , which further comprises producing the planar structure with the assistance of an extruder with a flat die or by casting the solution onto a level planar support.

22 . A process according to claim 19 , which further comprises shaping the dosage form by stamping from the dried planar structure or by calendaring.

23 . A process according to claim 19 , where the mixture is divided into portions such that, after drying, the portions correspond in each case to the mass of a unit of the dosage form.

24 . A process according to claim 23 , which further comprises placing the portions in molds corresponding to the shape of a unit of the dosage form.

25 . A process according to claim 19 , which further comprises dividing the mixture into any desired portions, and, after drying, optionally recombining the portions, and shaping to yield the dosage form.

26 . A process according to claim 1 , wherein the physiologically acceptable compounds and derivatives are salts, solvates, esters, ethers and amides.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
GRANT OF SECURITY INTEREST IN LICENSED PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0620 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Recorded Jul 12, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026577/0357 →
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Jul 8, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026561/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 9, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025456/0172 →